| Roberto D Latoni, MD | |
|
29 Calle Nelson Perea, Mayaguez, PR 00680-4946 | |
| (787) 831-5700 | |
| Not Available |
| Full Name | Roberto D Latoni |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 29 Years |
| Location | 29 Calle Nelson Perea, Mayaguez, Puerto Rico |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780675744 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | 14811 (Puerto Rico) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Insight Management Group Inc | 8527064062 | 5 |
News Archive
A program that targets allergens and tobacco smoke in the home resulted in fewer asthma symptoms in children participating in the intervention than in those who were not, according to a new study sponsored by the National Institutes of Health (NIH) in seven metropolitan areas nationwide.
Reducing the prevalence of obesity may prevent up to half of new Type 2 diabetes cases in the United States, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
A major goal of hospitals is to prevent unplanned readmissions of patients after they are discharged. A new study reveals that the preventability of readmissions changes over time: readmissions within the first week after discharge are often preventable by the hospital, whereas readmissions later are often related to patients' difficultly accessing outpatient clinics.
Arrowhead Pharmaceuticals Inc. today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.
› Verified 4 days ago
| Entity Name | Insight Management Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891722989 PECOS PAC ID: 8527064062 Enrollment ID: O20100727000180 |
News Archive
A program that targets allergens and tobacco smoke in the home resulted in fewer asthma symptoms in children participating in the intervention than in those who were not, according to a new study sponsored by the National Institutes of Health (NIH) in seven metropolitan areas nationwide.
Reducing the prevalence of obesity may prevent up to half of new Type 2 diabetes cases in the United States, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
A major goal of hospitals is to prevent unplanned readmissions of patients after they are discharged. A new study reveals that the preventability of readmissions changes over time: readmissions within the first week after discharge are often preventable by the hospital, whereas readmissions later are often related to patients' difficultly accessing outpatient clinics.
Arrowhead Pharmaceuticals Inc. today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.
› Verified 4 days ago
| Entity Name | American Radiology And Cardiovascular Inst. Of The San Antonio Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033289624 PECOS PAC ID: 3678904000 Enrollment ID: O20200519000466 |
News Archive
A program that targets allergens and tobacco smoke in the home resulted in fewer asthma symptoms in children participating in the intervention than in those who were not, according to a new study sponsored by the National Institutes of Health (NIH) in seven metropolitan areas nationwide.
Reducing the prevalence of obesity may prevent up to half of new Type 2 diabetes cases in the United States, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
A major goal of hospitals is to prevent unplanned readmissions of patients after they are discharged. A new study reveals that the preventability of readmissions changes over time: readmissions within the first week after discharge are often preventable by the hospital, whereas readmissions later are often related to patients' difficultly accessing outpatient clinics.
Arrowhead Pharmaceuticals Inc. today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Roberto D Latoni, MD Po Box 6043, Mayaguez, PR 00681-6043 Ph: (787) 831-5700 | Roberto D Latoni, MD 29 Calle Nelson Perea, Mayaguez, PR 00680-4946 Ph: (787) 831-5700 |
News Archive
A program that targets allergens and tobacco smoke in the home resulted in fewer asthma symptoms in children participating in the intervention than in those who were not, according to a new study sponsored by the National Institutes of Health (NIH) in seven metropolitan areas nationwide.
Reducing the prevalence of obesity may prevent up to half of new Type 2 diabetes cases in the United States, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
A major goal of hospitals is to prevent unplanned readmissions of patients after they are discharged. A new study reveals that the preventability of readmissions changes over time: readmissions within the first week after discharge are often preventable by the hospital, whereas readmissions later are often related to patients' difficultly accessing outpatient clinics.
Arrowhead Pharmaceuticals Inc. today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.
› Verified 4 days ago
Juan Miguel Delgado Polanco, M.D. Radiology Medicare: Medicare Enrolled Practice Location: Street 348 Estancias De San Benito, 701, Mayaguez, PR 00680 Phone: 787-473-2470 | |
Guillermo J Aguilo-ramos, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Frontera Colon & Suarez Radiologos, De Diego Street #12, Mayaguez, PR 00680 Phone: 787-834-4059 | |
Dr. Moises Orlando Acevedo Vazquez, MD Radiology Medicare: Medicare Enrolled Practice Location: 17 Calle Peral N, Mayaguez, PR 00680 Phone: 787-833-3168 Fax: 787-265-3191 | |
Dr. Daniel E. Valle, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 975 Ave Hostos Ste 2220, Mayaguez, PR 00680 Phone: 787-806-2900 Fax: 787-806-2226 | |
Sandra A Arroyo Ferrer, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2638 Ave Hostos, Edifiio Bioplaza Suite 101, Mayaguez, PR 00682 Phone: 787-805-2041 Fax: 787-986-7171 | |
Dr. Wanda I Benitez Lopez, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: Quintas De Santa Maria, 715, Mayaguez, PR 00682 Phone: 787-265-2471 | |
Dr. Virgen M Acosta Acosta, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 57 Calle De Diego E, Mayaguez, PR 00680 Phone: 787-833-4556 Fax: 787-265-3434 |